Neurocrine (NBIX) Stock Forecast & Price Target

Compare

1,389 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

NBIX Analyst Ratings

Strong Buy

20 Buy

2 Hold

0 Sell

Based on 22 analysts giving stock ratings to

Neurocrine

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

NBIX Stock 12 Month Forecast

Average Price Target

$160.24

▲(30.26%Upside)

Based on 22 Wall Street analysts offering 12 month price targets for Neurocrine in the last 3 months. The average price target is $160.24 with a high forecast of $192.00 and a low forecast of $115.00. The average price target represents a 30.26% change from the last price of $123.02.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"105":"$105","127":"$127","149":"$149","171":"$171","193":"$193"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":192,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$192.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":160.24,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$160.24</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":115,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$115.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[105,127,149,171,193],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Nov<br/>2024","9":"Feb<br/>2025","12":"May<br/>2025","25":"May<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,106.59,113.16,119.73,126.3,132.87,139.44,146.01,152.57999999999998,159.15,165.72,172.29,178.86,185.43,{"y":192,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,106.59,110.71692307692308,114.84384615384616,118.97076923076924,123.09769230769231,127.22461538461539,131.35153846153847,135.47846153846154,139.60538461538462,143.7323076923077,147.85923076923078,151.98615384615385,156.11307692307693,{"y":160.24,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,106.59,107.23692307692308,107.88384615384615,108.53076923076924,109.17769230769231,109.82461538461538,110.47153846153846,111.11846153846155,111.76538461538462,112.41230769230769,113.05923076923077,113.70615384615385,114.35307692307693,{"y":115,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":143.03,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":135.41,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":140.11,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":153.15,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":127.06,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":114.15,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 51,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":122.21,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":125.89,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":136.5,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":151.82,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":118.72,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":107,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":106.59,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$192.00

Average Price Target$160.24

Lowest Price Target$115.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

$133

Buy

8.11%

Upside

Reiterated

05/07/25

Neurocrine's stock score reflects its strong financial performance and promising developments in R&D, tempered by valuation concerns and operational challenges. While the company's financial stability and growth potential are significant strengths, high P/E ratio and reimbursement challenges pose risks. The technical analysis suggests mixed signals, indicating potential volatility.

Ami FadiaNeedham

Needham

$139

Buy

12.99%

Upside

Reiterated

05/28/25

Neurocrine's NBI-568 Clinical Advancements Justify Buy Rating Amid Competitive Efficacy and Strong Safety Profile

Paul MatteisStifel Nicolaus

Stifel Nicolaus

$174→$166

Buy

34.94%

Upside

Reiterated

05/26/25

Analysts Offer Insights on Healthcare Companies: Neurocrine (NASDAQ: NBIX), AnaptysBio (NASDAQ: ANAB) and ALX Oncology Holdings (NASDAQ: ALXO)

Uy EarMizuho Securities

Mizuho Securities

$140

Hold

13.80%

Upside

Reiterated

05/23/25

Analysts Offer Insights on Healthcare Companies: Neurocrine (NASDAQ: NBIX), Axsome Therapeutics (NASDAQ: AXSM) and Biogen (NASDAQ: BIIB)

Tazeen AhmadBank of America Securities

Bank of America Securities

$183

Buy

48.76%

Upside

Reiterated

05/14/25

Bank of America Securities Sticks to Their Buy Rating for Neurocrine (NBIX)

Anupam RamaJ.P. Morgan

J.P. Morgan

$184→$183

Buy

48.76%

Upside

Reiterated

05/14/25

Analysts Are Bullish on Top Healthcare Stocks: Codexis (CDXS), Neurocrine (NBIX)

Cory KasimovEvercore ISI

Evercore ISI

$185→$190

Buy

54.45%

Upside

Reiterated

05/06/25

Neurocrine Bio. (NBIX) PT Raised to $190 at Evercore ISIEvercore ISI analyst Cory Kasimov raised the price target on Neurocrine Bio. (NASDAQ: NBIX) to $190.00 (from $185.00) while maintaining a Outperform rating.

Myles MinterWilliam Blair

William Blair

―

Buy

―

Reiterated

05/06/25

Neurocrine's Strong Financial Performance and Strategic Initiatives Drive Buy Rating

Laura ChicoWedbush

Wedbush

$115→$130

Buy

5.67%

Upside

Reiterated

05/06/25

Wedbush Sticks to Its Buy Rating for Neurocrine (NBIX)

Andrew FeinH.C. Wainwright

H.C. Wainwright

$168

Buy

36.56%

Upside

Reiterated

05/06/25

Promising Growth Trajectory for Neurocrine: Buy Rating Justified by Strong Drug Performance and Innovative Trials

Sumant KulkarniCanaccord Genuity

Canaccord Genuity

$158→$160

Buy

30.06%

Upside

Reiterated

05/06/25

Neurocrine price target raised to $160 from $158 at CanaccordNeurocrine price target raised to $160 from $158 at Canaccord

David AmsellemPiper Sandler

Piper Sandler

$160→$154

Buy

25.18%

Upside

Reiterated

05/06/25

Piper Sandler Sticks to Their Buy Rating for Neurocrine (NBIX)

Ashwani VermaUBS

UBS

$137→$152

Buy

23.56%

Upside

Reiterated

05/06/25

Neurocrine price target raised to $152 from $137 at UBSNeurocrine price target raised to $152 from $137 at UBS

Joshua SchimmerCantor Fitzgerald

Cantor Fitzgerald

$170

Buy

38.19%

Upside

Reiterated

05/05/25

Analysts' Top Healthcare Picks: Neurocrine (NBIX), SI-Bone (SIBN)

Yatin SunejaGuggenheim

Guggenheim

$155→$165

Buy

34.12%

Upside

Reiterated

05/05/25

Guggenheim Sticks to Its Buy Rating for Neurocrine (NBIX)

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

$133

Buy

8.11%

Upside

Reiterated

05/07/25

Ami FadiaNeedham

Needham

$139

Buy

12.99%

Upside

Reiterated

05/28/25

Neurocrine's NBI-568 Clinical Advancements Justify Buy Rating Amid Competitive Efficacy and Strong Safety Profile

Paul MatteisStifel Nicolaus

Stifel Nicolaus

$174→$166

Buy

34.94%

Upside

Reiterated

05/26/25

Analysts Offer Insights on Healthcare Companies: Neurocrine (NASDAQ: NBIX), AnaptysBio (NASDAQ: ANAB) and ALX Oncology Holdings (NASDAQ: ALXO)

Uy EarMizuho Securities

Mizuho Securities

$140

Hold

13.80%

Upside

Reiterated

05/23/25

Analysts Offer Insights on Healthcare Companies: Neurocrine (NASDAQ: NBIX), Axsome Therapeutics (NASDAQ: AXSM) and Biogen (NASDAQ: BIIB)

Tazeen AhmadBank of America Securities

Bank of America Securities

$183

Buy

48.76%

Upside

Reiterated

05/14/25

Bank of America Securities Sticks to Their Buy Rating for Neurocrine (NBIX)

Anupam RamaJ.P. Morgan

J.P. Morgan

$184→$183

Buy

48.76%

Upside

Reiterated

05/14/25

Analysts Are Bullish on Top Healthcare Stocks: Codexis (CDXS), Neurocrine (NBIX)

Cory KasimovEvercore ISI

Evercore ISI

$185→$190

Buy

54.45%

Upside

Reiterated

05/06/25

Myles MinterWilliam Blair

William Blair

―

Buy

―

Reiterated

05/06/25

Neurocrine's Strong Financial Performance and Strategic Initiatives Drive Buy Rating

Laura ChicoWedbush

Wedbush

$115→$130

Buy

5.67%

Upside

Reiterated

05/06/25

Wedbush Sticks to Its Buy Rating for Neurocrine (NBIX)

Andrew FeinH.C. Wainwright

H.C. Wainwright

$168

Buy

36.56%

Upside

Reiterated

05/06/25

Promising Growth Trajectory for Neurocrine: Buy Rating Justified by Strong Drug Performance and Innovative Trials

Sumant KulkarniCanaccord Genuity

Canaccord Genuity

$158→$160

Buy

30.06%

Upside

Reiterated

05/06/25

Neurocrine price target raised to $160 from $158 at CanaccordNeurocrine price target raised to $160 from $158 at Canaccord

David AmsellemPiper Sandler

Piper Sandler

$160→$154

Buy

25.18%

Upside

Reiterated

05/06/25

Piper Sandler Sticks to Their Buy Rating for Neurocrine (NBIX)

Ashwani VermaUBS

UBS

$137→$152

Buy

23.56%

Upside

Reiterated

05/06/25

Neurocrine price target raised to $152 from $137 at UBSNeurocrine price target raised to $152 from $137 at UBS

Joshua SchimmerCantor Fitzgerald

Cantor Fitzgerald

$170

Buy

38.19%

Upside

Reiterated

05/05/25

Analysts' Top Healthcare Picks: Neurocrine (NBIX), SI-Bone (SIBN)

Yatin SunejaGuggenheim

Guggenheim

$155→$165

Buy

34.12%

Upside

Reiterated

05/05/25

Guggenheim Sticks to Its Buy Rating for Neurocrine (NBIX)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Neurocrine

1 Month

xxx

Success Rate

14/23 ratings generated profit

Average Return

+0.54%

reiterated a xxx

rating 27 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 60.87% of your transactions generating a profit, with an average return of +0.54% per trade.

3 Months

xxx

Success Rate

18/28 ratings generated profit

Average Return

+3.02%

reiterated a xxx

rating 19 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 64.29% of your transactions generating a profit, with an average return of +3.02% per trade.

1 Year

Tazeen AhmadBank of America Securities

Success Rate

18/28 ratings generated profit

Average Return

+6.81%

reiterated a buy rating 19 days ago

Copying Tazeen Ahmad's trades and holding each position for 1 Year would result in 64.29% of your transactions generating a profit, with an average return of +6.81% per trade.

2 Years

xxx

Success Rate

26/36 ratings generated profit

Average Return

+27.71%

reiterated a xxx

rating 7 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 72.22% of your transactions generating a profit, with an average return of +27.71% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

NBIX Analyst Recommendation Trends

Rating

Jan 25

Feb 25

Mar 25

Apr 25

May 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, NBIX has received 42 Buy Ratings, 6 Hold Ratings, and 0 Sell Ratings. NBIX average Analyst price target in the past 3 months is 160.24.

Each month's total comprises the sum of three months' worth of ratings.

NBIX Financial Forecast

NBIX Earnings Forecast

Next quarter’s earnings estimate for NBIX is $0.98 with a range of $0.49 to $1.37. The previous quarter’s EPS was $0.08. NBIX beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.04% of the time in the same period. In the last calendar year NBIX has Preformed in-line its overall industry.

NBIX Sales Forecast

Next quarter’s sales forecast for NBIX is $652.61M with a range of $612.49M to $682.70M. The previous quarter’s sales results were $572.60M. NBIX beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 47.36% of the time in the same period. In the last calendar year NBIX has Outperformed its overall industry.

NBIX Stock Forecast FAQ

What is NBIX’s average 12-month price target, according to analysts?

Based on analyst ratings, Neurocrine’s 12-month average price target is 160.24.

What is NBIX’s upside potential, based on the analysts’ average price target?

Neurocrine has 30.26% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is NBIX a Buy, Sell or Hold?

Neurocrine has a consensus rating of Strong Buy which is based on 20 buy ratings, 2 hold ratings and 0 sell ratings.

What is Neurocrine’s price target?

The average price target for Neurocrine is 160.24. This is based on 22 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $192.00 ,the lowest forecast is $115.00. The average price target represents 30.26% Increase from the current price of $123.02.

What do analysts say about Neurocrine?

Neurocrine’s analyst rating consensus is a Strong Buy. This is based on the ratings of 22 Wall Streets Analysts.

How can I buy shares of NBIX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Neurocrine (NBIX) Stock Forecast & Price Target

NBIX Analyst Ratings

NBIX Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Neurocrine

NBIX Analyst Recommendation Trends

NBIX Financial Forecast

NBIX Earnings Forecast

NBIX Sales Forecast

NBIX Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts